A cocktail of Cu²⁺- and Zn²⁺-peptoid-based chelators can stop ROS formation for Alzheimer's disease therapy.

ABSTRACT: The formation of reactive oxygen species (ROS) in the brain is a major cause of neuropathologic degradation associated with Alzheimer's Disease (AD). It has been suggested that the copper (Cu)-amyloid-β (Aβ) peptide complex can lead to ROS formation in the brain. An external chelator for Cu that can extract Cu from the CuAβ complex should inhibit the formation of ROS, making Cu chelation an excellent therapeutic approach for AD. Such a chelator should possess high selectivity for Cu over zinc (Zn), which is also present within the synaptic cleft. However, such selectivity is generally hard to achieve in one molecule due to the similarities in the binding preferences of these two metal ions. As an alternative to monotherapy (where Cu extraction is performed using a single chelator), herein

SUBMITTER: Behar AE 

PROVIDER: S-EPMC11503657 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature